<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/263331-a-ghrelin-analogue by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:22:12 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 263331:A GHRELIN ANALOGUE</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">A GHRELIN ANALOGUE</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The instant invention discloses compounds which are ghrelin analogues and pharmaceutically acceptable salts thereof capable of exhibiting ghrelin agonist activity.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td> <br><br>
This application is divided out of the Indian Patent Application no.: 1973/KOLNP/2004<br>
The pulsatile release of growth hormone from the pituitary somatotrops is<br>
regulated by two hypothalamic neuropeptides: growth hormone-releasing hormone<br>
and somatostatin. Growth hormone-releasing hormone stimulates release of growth<br>
hormone, whereas, somatostatin inhibits secretion of growth hormone. (Frohman et<br>
al., Endocr. Rev. 1986, 7, 223-253, and Strobi et al., Pharmacol. Rev. 1994, 46, 1-<br>
34.)<br>
Release of growth hormone from the pituitary somatotrops can also be<br>
controlled by growth hormone-releasing peptides (GHRP's). A hexapeptide, His-D-<br>
Trp-Ala-Trp-D-Phe-Lys-amide (GHRP-6), was found to release growth hormone from<br>
somatotrops in a dose-dependent manner in several species including man. (Bowers<br>
et al., Endocrinology 1984, 114, 1537-1545.) Subsequent chemical studies on<br>
GHRP-6 led to the identification of other potent growth hormone secretagogues such<br>
as GHRP-1, GHRP-2 and hexarelin (Cheng et al., Endocrinology 1989, 124, 2791-<br>
2798, Bowers, C. Y. Novel GH-Releasing Peptides. In: Molecular and Clinical<br>
Advances in Pituitary Disorders. Ed: Melmed, S.; Endocrine Research and<br>
Education, Inc., Los Angeles, CA, USA 1993, 153-157, and Deghenghi et al.. Life<br>
Sci. 1994, 54, 1321-1328):<br>
GHRP-1          Ala-His-D-(2')-Nal-Ala-Trp-D-Phe-Lys-NH2;<br>
GHRP-2         D-Ala-D-(2')-Nal-Ala-Trp-D-Nal-Lys-NH2;<br>
Hexarelin        His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2;.<br>
GHRP-1, GHRP-2, GHRP-6, and hexarelin are synthetic growth hormone<br>
secretagogues (GHS's). GHS's stimulate secretion of growth hormone by a<br>
mechanism different from that of growth hormone-releasing hormone. (Bowers et al..<br>
Endocrinology 1984, 114, 1537-1545, Cheng et al. Endocrinology 1989, 124, 2791-<br>
2798, Bowers, C. Y. Novel GH-Releasing Peptides. In: Molecular and Clinical<br>
Advances in Pituitary Disorders. Ed: Melmed, S.; Endocrine Research and<br>
Education, Inc., Los Angeles, CA, USA 1993, 153-157, and Deghenghi et al., Life<br>
Sci. 1994,54,1321-1328.)<br>
The low oral bioavailability (
secretagogues stimulated search for non-peptide compounds mimicking action of<br>
GHRP-6 in the pituitary. Several benzolactams and spiroindanes have been reported<br>
to stimulate growth hormone release in various animal species and in man. (Smith et<br>
al.. Science 1993, 260, 1640-1643, Patchett et al., Proc. Natl. Acad. Sci. USA. 1995,<br>
92, 7001-7005, and Chen et al., Bioorg. Mod. Chem. Lett. 1996, 6, 2163-2169.) A<br>
specific example of a small spiroindane is MK-0677 (Patchett et al. Proc. Natl. Acad.<br>
-1A-<br><br>
Sci. USA. 1995, 92, 7O01-7005):<br><br>
The actions of the above-mentioned GHS's (both peptide and non-peptide)<br>
appear to be mediated by a specific growth hormone secretagogue receptor (GHS<br>
receptor). (Howard et al., Science 1996, 273, 974-977, and Pong et al, Molecular<br>
Endocrinology 1996, 10, 57-61.) This receptor is present in the pituitary and<br>
hypothalamus of various mammalian species (GHSR1a) and is distinct from the<br>
growth hormone-releasing hormone (GHRH) receptor. The GHS receptor was also<br>
detected in the other areas of the central nervous system and in peripheral tissues,<br>
for instance adrenal and thyroid glands, heart, lung, kidney and skeletal muscles.<br>
(Chen et al, Bioorg. Med. Chem. Lett. 1996, 6, 2163-2169, Howard et al, Science<br>
1996, 273, 974-977, Pong et al, Molecular Endocrinology 1996, 10, 57-61, Guan et al,<br>
Mol. Brain Res. 1997, 48, 23-29, and McKee et al., Genomics 1997, 46, 426-434.) A<br>
truncated version of GHSR1a has been reported. (Howard et al., Science 1996, 273,<br>
974-977.)<br>
The GHS receptor is a G-protein coupled-receptor. Effects of GHS receptor<br>
activation include depolarization and inhibition of potassium channels, an increase in<br>
intercellular concentrations of inositol triphosphate (IP3), and a transient increase in<br>
the concentrations of intracellular calcium. (Pong et al, Molecular Endocrinology<br>
1996, 10, 57-61, Guan et al., Mol. Brain Res. 1997, 48, 23-29, and McKee et al.,<br>
Genomics 1997, 46, 426-434.)<br>
Ghrelin is a naturally occurring peptide which is believed to be an<br>
endogenous ligand for the GHS receptor. (Kojima et al., Nature 1999, 402, 656-660.)<br>
The native structures of ghrelins from several mammalian and non-mammalian<br>
species of animals are known. (Kaiya et al., J. Biol. Chem. 2001, 276, 40441-40448;<br>
International Patent Application PCT/JP00/04907 (WO 01/07475).) A core region<br>
present in ghrelin was found to provide for activity at the GHS receptor. The core<br>
region comprises the four N-terminal amino acids, where the serine at position 3 is<br>
normally modified with n-octanoic. However, in addition to acylation by n-octanoic<br>
acid native ghrelin also has been observed to be acylated with n-decanoic acid.<br>
(Kaiya et al., J. Biol. Chem. 2001, 276, 40441-40448.) Ghrelin analogs have a variety<br>
2<br><br>
of different therapeutic uses as well as uses as research tools.<br>
SUMMARY OF THE INVENTION<br>
The present invention features peptidyl analogs active at the GHS receptor.<br>
The analogs of the invention can bind to the GHS receptor and, preferably, bring<br>
about signal transduction.<br>
Thus, in a first aspect the present invention features a compound according to<br>
formula (1):<br>
R1-A1-A2-A3-A4-A5-R2<br>
(1)<br>
or a pharmaceutically acceptable salt thereof, wherein:<br>
A1 is Aib, Apc or Inp;<br>
A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(BzI), or D-Trp;<br>
A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl), or D-Trp;<br>
A4 is 2Fua, Om, 2Pal, 3Pal, 4Pal, Pff, Phe, Pirn, Taz, 2Thi, 3Thi, Thr(Bzl);<br>
A5 is Apc, Dab, Dap, Lys, Om, or deleted;<br>
R1 is hydrogen, (C1-6)alkyl, (C5-14)aryl, (C1-6)alkyI(C5.14)aryl, (C3-8)cycloakyl, or<br>
(C2.10)acyl; and<br>
R2 is OH or NH2;<br>
provided that<br>
when A5 is Dab, Dap, Lys, or Orn, then:<br>
A2 is D-Bip, D-Bpa, D-Dip or D-Bal; or<br>
A3 is D-Bip, D-Bpa, D-Dip or D-Bal; or<br>
A4 is 2Thi, 3Thi, Taz, 2Fua, 2Pal, 3Pal, 4Pal, Om, Thr(Bzl), or Pff;<br>
when A5 is deleted, then:<br>
A3 is D-Bip, D-Bpa, or D-Dip; or<br>
A4 is 2Fua, Pff, Taz, or Thr(Bzl); or<br>
A1 is Apc and -<br>
A2 is D-Bip, D-Bpa, D-Dip or D-Bal; or<br>
A3 is D-Bip, D-Bpa, D-Dip or D-Bal; or<br>
A4 is 2Thi, 3Thi, Orn, 2Pal, 3Pal, or 4Pal.<br>
A preferred compound of formula (I), termed a Group 1 compound, is a<br>
compound according to formula (I) wherein:<br>
A1 is Aib, Apc or H-lnp;<br>
A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl), or D-Trp;<br>
A3 is D-Bal, D-Bpa, D-Dip, D-1 Nal, D-2Nal, or D-Trp;<br>
A4 is Om, 3Pal, 4Pal, Pff, Phe, Pirn, Taz, 2Thi, or Thr(Bzl); and<br>
3<br><br>
A5 is Ape, Lys, or deleted;<br>
or a phamnaceutically acceptable salt thereof.<br>
A preferred Group 1  compound, termed a Group 1A compound, is a<br>
compound according to the formula:<br>
A1 is Ape or H-lnp;<br>
A2 is D-Bal, D-Bip, D-1Nal, or D-2Nal;<br>
A3 is D-Bal, D-1Nal, D-2Nal, or D-Trp;<br>
A4 is 3Pal, 4PaI, Pff, Phe, Pirn, Taz, 2Thi, or Thr(Bzl); and<br>
or a pharmaceutically acceptable salt thereof.<br>
Another preferred compound of formula (1), termed a Group 2 compound, is a<br>
compound according to the formula:<br>
H-lnp-D-1Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-4Pal-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Orn-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Dip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-Bpa-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Bpa-Phe-Lys-NH2;<br>
H-lnp-D-2NaJ-D-Trp-3Pal-NH2;<br>
H-lnp-D-2Nal-D-Trp-4Pal-NH2;<br>
H-lnp-D-1 Nal-D-Trp-3Pal-NH2<br>
H-lnp-D-Bip-D-Trp-Phe-NH2;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-Dip-D-Trp-Phe-NH2;<br>
H-lnp-D-2Nal-D-Dip-Phe-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-NH2;<br>
H-lnp-D-2Nal-D-Bal-Phe-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-Trp-D-2Nal(Ψ)-Pim;<br>
H-lnp-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
4<br><br>
H-lnp-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
H-lnp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-lnp-D-1Nal-D-Trp(Ψ)-Pim;<br>
H-lnp-D-Bal-D-Trp(Ψ)-Pim;<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
H-lnp-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-1Nal-D-1 Nal-Phe-Apc-NH2;<br>
H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH2;<br>
H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-1Nal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-1Nal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-1 Nal-D-Trp-Taz-Apc-NH2;<br>
H-Inp-D-Bal-D-Trp-Taz-Apc-NH2;<br>
5<br><br>
H-Apc-D-1Nal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Apo-NH2;<br>
H-Apc-D-1 Nal-D-Trp-2Fua-Apc-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Fua-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Fua-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Pal-NH2;<br>
H-Apc-D-1Nal-D-Trp-3Pal-NH2;<br>
H-Apc-D-1Nal-D-Trp-3Thi-Apc-NH2;<br>
H-Apc-D-1Nal-D-Trp-3Thi-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-3Thi-NH2;<br>
H-Apc-D-1Nal-D-Trp-4Pal-NH2;<br>
H-Apc-D-1Nal-D-Trp-Pff-Apc-NH2;<br>
H-Apc-D-1Nal-D-Trp-Pff-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Pff-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Fua-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Fua-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Fua-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Pal-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-Apc-NH2;<br>
H-Apc-D-2NaI-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-3Pal-NH2;<br>
H-Apc-D-2Nal-D-Trp-3Thi-Apc-NH2;<br>
H-Apc-D-2NaI-D-Trp-3Thi-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-3Thi-NH2;<br>
H-Apc-D-2Nal-D-Trp-4Pal-NH2;<br>
H-Apc-D-2Nal-D-Tfp-Pff-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Pff-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Pff-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-2Fua-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-2Fua-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-2Fua-NH2<br>
H-Apc-D-Bal-D-Bal-2Pal-NH2;<br>
H-Apc-D-BaI-D-Bal-2Thi-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-2Thi-NH2;<br>
6<br><br>
H-Apc-D-Bal-D-Bal-3Pal-NH2;<br>
H-Apc-D-Bal-D-Bal-3Thi-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-3Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-3Thi-NH2;<br>
H-Apc-D-Bal-D-Bal-4PaI-NH2;<br>
H-Apc-D-Bal-D-Bal-Pff-Apc-NH2;<br>
H-Apc--D-Bal-D-Bal-Pff-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-Pff-N H2;<br>
H-Apc-D-Bal-D-Bal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-Phe-NH2;<br>
H-Apc-D-Bal-D-Bal-Taz-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Ba!-Taz-NH2;<br>
H-Apc-D-Bal-D-Trp-2Fua-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-2Fua-Lys-NH2;<br>
H-Apc-D-Bal-D-Tip-2Fua-NH2;<br>
H-Apc-D-Bal-D-Trp-2Pal-NH2;<br>
H-Apc-D-Bal-D-Trp-3Pal-NH2;<br>
H-Apc-D-Bal-D-Trp-3Thi-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-3Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-3Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-4Pal-NH2;<br>
H-Apc-D-Bal-D-Trp-Pff-Apc-NH2;<br>
H-Apc-D-Ba!-D-Trp-Pff-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Pff-NH2;<br>
H-lnp-D-1Nal-D-Bal-2Fua-Lys-NH2;<br>
,H-lnp-D-1Nal-D-Ba-2Fua-NH2;<br>
H-lnp-D-1Nal-D-Bal-2Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-3Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-Pff-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-Pff-NH2;<br>
H-lnp-D-1Nal-D-Bal-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-Taz-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-Taz-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Fua-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Fua-Lys-NH2;<br>
7<br><br>
H-lnp-D-1Nal-D-Trp-2Fua-NH2;<br>
H-lnp-D-1Nal-D-Trp-3Thi-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-3Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-Pff-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-Pff-NH2;<br>
H-lnp-D-1Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Fua-Apc-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Fua-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Thi-Apc-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Thi-Apc-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Thi-Lys-NH2;<br>
H-Inp-D-2Nal-D-Trp-3Thi-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-Apc-NH2;<br>
H-lnp-D-2Nai-D-Trp-Pff-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-Apo-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-Bal-D-Bal-2Fua-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-2Fua-NH2;<br>
H-lnp-D-Bal-D-Bal-2Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-3Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-Pff-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-Pff-NH2;<br>
H-Inp-D-Ba!-D-Bal-Phe-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-Taz-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-Taz-NH2;<br>
H-lnp-D-Bal-D-Trp-2Fua-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-2Fua-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-2Fua-NH2;<br>
H-lnp-D-Bal-D-Trp-3Thi-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-3Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Pff-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Pff-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-NH2;<br>
H-lnp-D-Bip-D-Bal-2Fua-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-2Fua-NH2;<br>
8<br><br>
H-lnp-D-Bip-D-Bal-2Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-3Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-Pff-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-Pff-NH2; or<br>
H-lnp-D-Bip-D-Bal-Taz-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-Taz-NH2;<br>
H-lnp-D-Bip-D-Trp-2Fua-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-2Fua-NH2;<br>
H-lnp-D-Bip-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-3Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Pff-NH2;<br>
H-lnp-D-Bip-D-Trp-Taz-Lys-NH2; or<br>
H-Inp-D-Bip-D-Trp-Taz-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
A preferred Group 2 compound, termed a Group 2A compound, is a<br>
compound according to the formula:<br>
H-lnp-D-1Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-4Pal-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Orn-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Thl-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Dip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-Bpa-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Bpa-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-2Nal-D-Dip-Phe-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-Trp-D-2Nal(Ψ)-Pim;<br>
H-lnp-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-1NaI-D-Trp-2Thi-Lys-NH2;<br>
9<br><br>
H-lnp-D-2Nal-D-Trp-Phe-Apc-NH2;<br>
H-Inp-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-lnp-D-1Nal-D-Trp(Ψ)-Pim;<br>
H-lnp-D-BaI-D-Trp(Ψ)-Pim;<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
H-lnp-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-1 Nal-D-1Nal-Phe-Apc-NH2;<br>
H-Apc-D-1 Nal-D-2Nal-Phe-Apc-NH2;<br>
H-Apc-D-1 Nal-D-1 Nal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-1Nal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-1Nal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-1Nal-D-Trp-Taz-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Apc-NH2;<br>
H-lnp-D-2NaI-D-Trp-3Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-3Thi-Lys-NH2;<br>
10<br><br>
H-lnp-D-BaI-D-Trp-2Fua-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-3Thi-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-2Fua-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Pff-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-3Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-2Fua-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-Phe-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-2Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-3Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-Taz-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-2Fua-Lys-NH2;<br>
H-lnp-D-Bal-D-Bal-Pff-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-3Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-2Fua-Lys-NH2;<br>
H-Apc-D-Bal-D-Bal-Pff-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-3Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Fua-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-2Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-3Thi-Lys-NH2;<br>
H-lnp-D-1NaI-D-Bal-Taz-Lys-NH2;<br>
H-lnp-D-1Nal-D-Bal-2Fua-Lys-NH2;<br>
H-lnp-D-1Nal-D-BaI-Pff-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Thi-Apc-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Thi-Apc-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-Apc-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Fua-Apc-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-Apc-NH2;<br>
H-lnp-D-1 Nal-D-Trp-3Thi-Apc-NH2;<br>
H-lnp-D-1 Nal-D-Trp-2Fua-Apc-NH2;<br>
H-lnp-D-1 Nal-D-Trp-Pff-Apc-NH2;<br>
11<br><br>
H-Apc-D-1Nal-D-Trp-3Thi-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Fua-Lys-N H2;<br>
H-Apc-D-1Nal-D-Trp-Pff-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-3Thi-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-Lys-NH2;<br>
H-ApoD-2NaI-D-Trp-2Fua-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-3Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-2Fua-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-2Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-3Thi-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-Taz-Lys-NH2;<br>
H-lnp-D-Bip-D-Bal-2Fua-Lys-NH2;<br>
H-lnp-D-Bip-D-BaI-Pff-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-3Thi-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-2Fua-Apc-NH2;<br>
H-Apc-D-BaI-D-Trp-Pff-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-Ba!-2Thi-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-3Thi-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-Taz-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-2Fua-Apc-NH2;<br>
H-Apc-D-Bal-D-Bal-Pff-Apc-NH2;<br>
H-Apc-D-1 NaI-D-Trp-3Thi-Apc-NH2;<br>
H-Apc-D-1 Nal-D-Trp-2Fua-Apc-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Pff-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-3Thi-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Fua-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Pff-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-NH2;<br>
H-lnp-D-Bal-D-Trp-2Fua-NH2;<br>
12<br><br>
H-Inp-D-Bal-D-Trp-Pff-NH2;<br>
H-Apc-D-BaI-D-Trp-3Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-2Fua-NH2;<br>
H-Apc-D-Bal-D-Trp-Pff-NH2;<br>
H-Apc-D-Bal-D-Trp-4Pal-NH2;<br>
H-Apc-D-Bal-D-Trp-3PaI-NH2;<br>
H-Apc-D-Bal-D-Trp-2Pal-NH2;<br>
H-lnp-D-Bal-D-Bal-Taz-NH2;<br>
H-lnp-D-Bal-D-Bal-2Fua-NH2;<br>
H-lnp-D-Bal-D-Bal-Pff-NH2;<br>
H-Apc-D-Bal-D-Bal-Phe-NH2;<br>
H-Apc-D-Bal-D-Bal-2Thi-NH2;<br>
H-Apc-D-Bal-D-Bal-3Thi-NH2;<br>
H-Apc-D-Bal-D-Bal-Taz-NH2;<br>
H-Apc-D-Bal-D-Bal-2Fua-NH2;<br>
H-Apc-D-Bal-D-Bal-Pff-NH2;<br>
H-Apc-D-Bal-D-Bal-4Pal-NH2;<br>
H-Apc-D-Bal-D-Bal-3Pal-NH2;<br>
H-Apc-D-Bal-D-Bal-2Pal-NH2;<br>
H-lnp-D-1Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Fua-NH2;<br>
H-lnp-D-1Nal-D-Trp-Pff-NH2;<br>
H-lnp-D-1Nal-D-Bal-Taz-NH2;<br>
H-lnp-D-1Nal-D-Bal-2Fua-NH2;<br>
H-lnp-D-1Nal-D-Bal-Pff-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Fua-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-NH2;<br>
H-Apc-D-1Nal-D-Trp-3Thi-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Fua-NH2;<br>
H-Apc-D-1Nal-D-Trp-Pff-NH2;<br>
H-Apc-D-1Nal-D-Trp-4Pal-NH2;<br>
H-Apc-D-1Nal-D-Trp-3Pal-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Pal-NH2;<br>
H-Apc-D-2NaI-D-Trp-3Thi-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Fua-NH2;<br>
H-Apc-D-2Nal-D-Trp-Pff-NH2;<br>
13<br><br>
H-Apc-D-2Nal-D-Trp-4Pal-NH2;<br>
H-Apc-D-2Nal-D-Trp-3Pal-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Pal-NH2;<br>
H-Inp-D-Bip-D-Trp-Taz-NH2;<br>
H-lnp-D-Bip-D-Trp-2Fua-NH2;<br>
H-lnp-D-Bip-D-Trp-Pff-NH2;<br>
H-lnp-D-Bip-D-Bal-Taz-NH2;<br>
H-lnp-D-Bip-D-Bal-2Fua-NH2; or<br>
H-lnp-D-Bip-D-Bal-Pff-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
A preferred Group 2A compound, termed a Group 2B compound, is a<br>
compound according to the formula:<br>
H-lnp-D-1Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-4Pal-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Om-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Dip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-Bpa-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Bpa-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp(Ψ)-Pim;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-NH2;<br>
H-lnp-D-2Nal-D-Trp(Ψ)-Pim:<br>
H-lnp-D-Trp-D-2Nal(Ψ)-Pim;<br>
H-lnp-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-2Nal-D-Dip-Phe-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Lys-NH2;<br>
14<br><br>
H-Apc-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-1Nal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-2NaI-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-Taz-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-Bal-D-1NaI-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Apc-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-1 Nal-D-1Nal-Phe-Apc-NH2;<br>
H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp(Ψ)-Pim;<br>
H-Apc-D-Bal-D-Trp-Phe-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-NH2;<br>
H-Apc-D-1 Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Taz-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-NH2; or<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
or a pharmaceutically acceptable salt thereof.<br>
A preferred Group 2B compound, termed a Group 2B-1 compound, is a<br>
compound according to the formula:<br>
H-lnp-D-1Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-4Pal-Lys-NH2;<br>
H-lnp-D-Bip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-Lys-NH2;<br>
15<br><br>
H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Thr(Bzl)-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Pal-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-1NaI-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Lys-NH2; '<br>
H-Apc-D-1 Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-1 Nal-D-1Nal-Phe-Apc-NH2;<br>
H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH2;<br>
H-Apc-D-1 Nal-D-1Nal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-1 Nal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-1Nal-Phe-Lys-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-2Nal-D-Trp-Taz-NH2;<br>
H-lnp-D-1Nal-D-Trp-Taz-Apc-NH2;<br>
16<br><br>
H-lnp-D-Bal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-Apc-NH2; or<br>
H-Apc-D-Bal-D-Trp-Taz-Apc-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
A preferred Group 2B-1 compound, termed a Group 2B-1a compound, is a<br>
compound according to the formula:<br>
H-lnp-D-1Nal-D-Trp-3Pal-Lys-NH2;<br>
H-Inp-D-2Nal-D-Tip-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-1 Nal-D-Trp-Taz-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-Bal-D-2Nal-Phe-Lys-NH2;<br>
H-Apc-D-1 Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-NH2;<br>
H-Apc-D-Ba!-D-Trp-2Thi-NH2;<br>
H-Apc-D-2Nal-D-Trp-2Thi-NH2;<br>
H-lnp-D-1 Nal-D-Trp-Taz-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Taz-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Apc-N H2; or<br>
or a pharmaceutically acceptable salt thereof.<br>
17<br><br>
A more preferred Group 2B-1 compound, termed a Group 2B-1 b compound,<br>
is a compound according to the formula:<br>
H-lnp-D-2Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-BaI-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-1Nal-D-Trp-Phe-Apc-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH2;<br>
H-Inp-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Apc-NH2; or<br>
H-Apc-D-2Nal-D-Trp-2Thi-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
A still more preferred Group 2B-1  compound termed a Group 2B-1c<br>
compound, is a compound according to the formula:<br>
H-Inp-D-2Nal-D-Trp-2Thi-Lys-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-Apc-NHz;<br>
H-Apc-D-1 Nal-D-Trp-2Thi-Lys-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Taz-Lys-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
A particularly preferred Group 2B-1c compound is a compound according to<br>
the formula:<br>
H-lnp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
Another still more preferred Group 2B-1 compound, termed a Group 2B-1d<br>
compound, is a compound according to the formula:<br>
H-Inp-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-1Nal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-Bal-D-Trp-Taz-Lys-NH2;<br>
H-Apc-D-1 Nal-D-Trp-Phe-Apc-NH2; or<br>
or a pharmaceutically acceptable salt thereof.<br>
18<br><br>
Another preferred Group 2B compound, termed a Group 2B-2 compound, is a<br>
compound according to the formula:<br>
H-lnp-D-2Nal-D-Trp-Orn-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Dip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-Bpa-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Bpa-Phe-Lys-NH2;<br>
H-lnp-D-2Na!-D-Trp-Pff-NH2;<br>
H-lnp-D-2Nal-D-Dip-Phe-NH2;<br>
H-lnp-D-Trp-D-2Nal(Ψ)-Pim;<br>
H-lnp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-lnp-D-1Na-D-Trp(Ψ)-Pim;<br>
H-lnp-D-Bal-D-Trp(Ψ)-Pim; or<br>
H-Aib-D-Ser(BzI)-D-Trp(Ψ)-Pim;<br>
or a pharmaceutically acceptable salt thereof.<br>
A preferred Group 2B-2 compound, termed a Group 2B-2a compound, is a<br>
compound according to the formula:<br>
H-lnp-D-2Nal-D-Trp-Pff-Lys-NH2;<br>
H-lnp-D-Dip-D-Trp-Phe-Lys-NH2;<br>
H-lnp-D-2Nal-D-Trp-Pff-NH2;<br>
H-lnp-D-1Na-D-Trp(Ψ)-Pim; or<br>
H-lnp-D-Bal-D-Trp(Ψ)-Pim;<br>
or a pharmaceutically acceptable salt thereof.<br>
Another preferred Group 2 compound, termed a Group 2C compound, is a<br>
compound according to the formula:<br>
H-lnp-D-2Nal-D-Trp-3Pal-NH2;<br>
H-lnp-D-2Nal-D-Trp-4Pal-NH2;<br>
H-lnp-D-1 Nal-D-Trp-3Pal-NH2;<br>
H-lnp-D-Bip-D-Trp-Phe-NH2;<br>
H-lnp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-lnp-D-2Nal-D-Trp-3Thi-NH2;<br>
H-lnp-D-Dip-D-Trp-Phe-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-NH2;<br>
H-lnp-D-2Nal-D-Bal-Phe-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-NH2; or<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
19<br><br>
A preferred Group 2C compound, termed a Group 2C-1 compound, is a<br>
compound according to the formula:<br>
H-lnp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-lnp-D-Bal-D-Trp-Phe-NH2;<br>
H-lnp-D-1Nal-D-Trp-2Thi-NH2; or<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
A particularly preferred compound of the invention, termed a Group 3<br>
compound, is a compound according to the formula:<br>
H-Inp-D-1Nal-D-Trp-2Thi-Apc-NH2;<br>
H-lnp-D-Bal-D-Trp-2Thi-Apc-NH2;<br>
H-Apc-D-1Nal-D-Trp-2Thi-Apc-NH2;<br>
H-Apc-D-Bal-D-Trp-2Thi-Apc-NH2; or<br>
H-Apc-D-1Nal-D-Trp-Phe-Lys-NH2;<br>
or a pharmaceutically acceptable salt thereof.<br>
In another aspect the invention features a method of determining a<br>
compound's ability to bind to a GHS receptor, said method comprising the step of<br>
measuring the ability of a compound to affect binding of a compound according to<br>
formula (I) or according to any one of Groups 1, 1A, 2, 2A, 2B, 2B-1, 2B-1a, 2B-1b,<br>
2B-1c, 2B-1d, 2B-2, 2B-2a, 2C, or 2C-1 to said receptor, to a fragment of said<br>
receptor, to a polypeptide comprising said fragment of said receptor, or to a<br>
derivative of said polypeptide.<br>
In another aspect the invention features a method for achieving a beneficial<br>
affect in a subject comprising, said method comprising the step of administering to<br>
said subject an effective amount of a compound according to formula (I), Group 1,<br>
Group 1 A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b,<br>
Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or<br>
a pharmaceutically acceptable salt thereof, wherein said effective amount is effective<br>
for producing a beneficial effect in helping to treat (e.g., cure or reduce the severity)<br>
or prevent (e.g., reduce the likelihood of onset or severity) a disease or disorder.<br>
In another aspect the invention features a method for stimulating growth<br>
hormone secretion in a subject in need of such stimulation, comprising the step of<br>
administering to a subject an effective amount of a ghrelin agonist according to<br>
formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group<br>
2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group<br>
2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said<br>
effective amount is at least an amount sufficient to produce a detectable increase in<br>
20<br><br>
growth hormone secretion and, preferably, is an amount sufficient to achieve a<br>
beneficial affect in a patient<br>
In one embodiment of the immediately foregoing aspect said stimulation of<br>
growth hormone secretion is indicated for treatment of a growth hormone deficient<br>
state, for increasing muscle mass, for increasing bone density, for sexual dysfunction<br>
in males or females, for facilitating a weight gain, for facilitating maintenance of<br>
weight, for facilitating maintenance of physical functioning, for facilitating recovery of<br>
physical function, and/or facilitating appetite increase. Preferably said facilitating<br>
weight gain, facilitating maintenance in weight and/or facilitating appetite increase is<br>
indicated in a patient having a disease or disorder, or under going a treatment,<br>
accompanied by weight loss. More preferably said diseases or disorders<br>
accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, (e.g.,<br>
wasting), cachexia, and wasting in frail elderly. Also preferably said treatments<br>
accompanied by weight loss include chemotherapy, radiation therapy, temporary or<br>
permanent immobilization, and dialysis.<br>
In another aspect the invention features a method for suppressing growth<br>
hormone secretion in a subject in need of such suppression, comprising the step of<br>
administering to a subject an effective amount of a ghrelin antagonist according to<br>
formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group<br>
2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group<br>
2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said<br>
effective amount is at least an amount sufficient to produce a detectable decrease in<br>
growth hormone secretion and, preferably, is an amount sufficient to achieve a<br>
beneficial affect in a patient<br>
In one embodiment of the immediately foregoing aspect said suppression of<br>
growth hormone secretion is indicated for the treatment of a disease or condition<br>
characterized by excessive growth hormone secretion, for facilitation of weight loss,<br>
For facilitation of appetite decrease, for facilitation of weight maintenance, for treating<br>
obesity, for treating diabetes, for treating complications of diabetes including<br>
retinopathy, and/or for treating cardiovascular disorders.<br>
In a preferred embodiment of the immediately foregoing aspect excessive<br>
weight is a contributing factor to a disease or condition including hypertension,<br>
diabetes, dyslipidemia, cardiovascular disease, gall stones, osteoarthritis and<br>
cancers. More preferably said facilitation of weight loss reduces the likelihood of such<br>
diseases or conditions. Also more preferably said facilitation of weight loss comprises<br>
at least part of a treatment for such diseases or conditions.<br>
A method of eliciting a ghrelin agonist effect in a subject, comprising the step<br>
21<br><br>
of administering to a subject an effective amount of one or more of a ghrelin agonist<br>
according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group<br>
2B-1, Group 2B-1a, Group 2B-1 b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group<br>
2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof,<br>
wherein said effective amount is at least an amount sufficient to produce a detectable<br>
increase in growth hormone secretion and, preferably, is an amount sufficient to<br>
achieve a beneficial affect in a patient.<br>
In another aspect the invention features a method of eliciting a ghrelin<br>
antagonist effect in a subject, comprising the step of administering to a subject an<br>
effective amount of one or more of a ghrelin antagonist according to formula (1),<br>
Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group<br>
2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group<br>
2C-1, or a pharmaceutically acceptable salt thereof, wherein said effective amount is<br>
at least an amount sufficient to produce a detectable decrease in growth hormone<br>
secretion and, preferably, is an amount sufficient to achieve a beneficial affect in a<br>
patient.<br>
Compounds of the invention are active at the GHS receptor. The compounds<br>
can bind to the receptor, and preferably, stimulate receptor activity. Thus a<br>
compound of the invention is useful as a functional ghrelin analog, both as a<br>
research tool and/or as a therapeutic agent.<br>
Research tool applications generally involve the use of a compound of the<br>
invention and the presence of a GHS receptor or fragment thereof. The GHS<br>
receptor can be present in different environments such as a mammalian subject, a<br>
whole cell, or a cell membrane fragment Examples of research tool applications<br>
include screening for compounds active at the GHS receptor, determining the<br>
presence of the GHS receptor in a sample or preparation, and examining the role or<br>
effect of ghrelin.<br>
One aspect of the present invention features a method of screening for<br>
ghrelin agonists and/or for ghrelin antagonists. Screening for ghrelin agonists can be<br>
performed, for example, by using a compound according to formula (I), Group 1,<br>
Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b,<br>
Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or<br>
a pharmaceutically acceptable salt thereof, in a competition experiment with test<br>
compounds. Screening for ghrelin antagonists can be performed, for example, by<br>
using a compound according to formula (I), Group 1, Group 1A, Group 2, Group 2A,<br>
Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d,<br>
Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically<br>
22<br><br>
acceptable salt thereof, to produce GHS receptor activity and then measuring the<br>
ability of a test compound to alter GHS receptor activity.<br>
Another aspect of the present invention features a method of screening for a<br>
compound able to bind to a GHS receptor. The method comprises the step of<br>
measuring the ability of a test compound to affect the binding of a compound<br>
according to formula (I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group<br>
2B-1, Group 2B-1a, Group 2B-1b, Group_2B-1c, Group 2B-1d, Group 2B-2, Group<br>
2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically acceptable salt thereof, to<br>
either the receptor, a fragment of the receptor comprising a ghrelin binding site, a<br>
polypeptide comprising the fragment, or a derivative of the polypeptide.<br>
Ghrelin agonists can be used to achieve a beneficial effect in a subject. For<br>
example, ghrelin induces growth hormone release from primary-culture pituitary cells<br>
in a dose-dependent manner without stimulating the release of the other pituitary<br>
hormones. Injected intravenously info anaesthetized rats, ghrelin stimulated pulsatile<br>
release of growth hormone. (Kojima et a/.. Nature 1999, 402, 656-660.) Thus a non-<br>
exclusive list of examples wherein such a beneficial effect may be indicated would<br>
include: treating a growth hormone deficient state, increasing muscle mass,<br>
increasing bone density, treating sexual dysfunction in males or females, facilitating a<br>
weight gain, facilitating maintenance of weight, facilitating maintenance of physical<br>
functioning, facilitating recovery of physical function, and/or facilitating appetite<br>
increase. Facilitating a weight gain, maintenance in weight, or appetite increase is<br>
particularly useful for a subject having a disease or disorder, or undergoing a<br>
treatment, accompanied by weight loss. Diseases or disorders accompanied by<br>
weight loss include, e.g., anorexia, bulimia, cancer cachexia, AIDS, (e.g., wasting),<br>
cachexia, wasting in frail elderly, and the like. Treatments accompanied by weight<br>
loss include, e.g., chemotherapy, radiation therapy, temporary or permanent<br>
immobilization, dialysis, and the like.<br>
Thus another aspect of the present invention features a method for achieving<br>
a beneficial affect in a subject said method comprising the step of administering to<br>
said subject an effective amount of one or more of a compound according to formula<br>
(I), Group 1, Group 1A, Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a,<br>
Group 2B-1b, Group 2B-1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or<br>
Group 2C-1, or a pharmaceutically acceptable salt thereof, wherein said effective<br>
amount is effective for producing a beneficial effect in helping to treat (e.g., cure or<br>
reduce the severity of) or prevent (e.g., reduce the likelihood of onset or severity of) a<br>
disease or disorder.<br>
In a preferred embodiment of the   immediately preceding method said<br>
23<br><br>
beneficial affect comprises stimulating growth hormone secretion in a subject in need<br>
of such stimulation, comprising the step of administering to a subject an effective<br>
amount of one or more of a compound according to formula (I), Group 1, Group 1A,<br>
Group 2, Group 2A, Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-<br>
1c, Group 2B-1d, Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a<br>
pharmaceutically acceptable salt thereof, wherein said effective amount is at least an<br>
amount sufficient to produce a detectable increase in growth hormone secretion and,<br>
preferably, is an amount sufficient to achieve a beneficial affect in a patient<br>
In a more preferred embodiment of the immediately preceding method said<br>
stimulation of growth hormone secretion is indicated for treatment of a growth<br>
hormone deficient state, for increasing muscle mass, for increasing bone density, for<br>
sexual dysfunction in males or females, for facilitating a weight gain, for facilitating<br>
maintenance of weight, for facilitating maintenance of physical functioning, for<br>
facilitating recovery of physical function, and/or facilitating appetite increase.<br>
In another preferred embodiment of the immediately preceding method said<br>
facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite<br>
increase is indicated in a patient having a disease or disorder, or under going a<br>
treatment, accompanied by weight loss. More preferably said diseases or disorders<br>
accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, (e.g.,<br>
wasting), cachexia, and wasting in frail elderly.<br>
In another more preferred embodiment of the immediately preceding method<br>
said treatments accompanied by weight loss indude chemotherapy, radiation<br>
therapy, temporary or permanent immobilization, and dialysis.<br>
Ghrelin antagonists can also be used to achieve a beneficial effect in a<br>
patient. For example, a ghrelin antagonist can be used to facilitate weight loss,<br>
facilitate appetite decrease, facilitate weight maintenance, treat obesity, treat<br>
diabetes, treat complications of diabetes including retinopathy, and/or treat<br>
cardiovascular disorders. Excessive weight is a contributing factor to different<br>
diseases including hypertension, diabetes, dyslipidemias, cardiovascular disease,<br>
gall stones, osteoarthritis and certain forms of cancers. Bringing about a weight loss<br>
can be used, for example, to reduce the likelihood of such diseases and as part of a<br>
treatment for such diseases.<br>
Compounds of the invention may also antagonize the effects of ghrelin in vitro<br>
and in vivo. Thus yet another aspect of the present invention features a method for<br>
suppressing growth hormone secretion in a subject in need of such suppression,<br>
comprising the step of administering to a subject an effective amount of one or more<br>
of a compound according to formula (I), Group 1, Group 1A, Group 2, Group 2A,<br>
24<br><br>
Group 2B, Group 2B-1, Group 2B-1a, Group 2B-1b, Group 2B-1c, Group 2B-1d,<br>
Group 2B-2, Group 2B-2a, Group 2C, or Group 2C-1, or a pharmaceutically<br>
acceptable salt thereof, wherein said effective amount is at least an amount sufficient<br>
to produce a detectable decrease in growth hormone secretion and, preferably, is an<br>
amount sufficient to achieve a beneficial affect in a patient<br>
In a preferred embodiment of the immediately preceding method said<br>
suppression of growth hormone secretion is indicated for the treatment of a disease<br>
or condition characterized by excessive growth hormone secretion, for facilitation of<br>
weight loss, for facilitation of appetite decrease, for facilitation of weight maintenance,<br>
or treating obesity, for treating diabetes, for treating complications of diabetes<br>
including retinopathy, and/or for treating cardiovascular disorders.<br>
In a more preferred embodiment of the immediately preceding method<br>
excessive weight is a contributing factor to a disease or condition including<br>
hypertension, diabetes, dyslipidemia, cardiovascular disease, gall stones,<br>
steoarthritis and cancers.<br>
In another more preferred embodiment of the immediately preceding method<br>
aid facilitation of weight loss reduces the likelihood of such diseases or conditions<br>
and/or said facilitation of weight loss comprises at least part of a treatment for such<br>
diseases or conditions.<br>
As is also appreciated by those of skill in the art, ghrelin and agonists thereof<br>
lay also be used to achieve beneficial cardiovascular effects. (Nagaya, et al., Regul<br>
ept. 2003 Jul 15: 114(2-3): 71-77.) For example, it is known that ghrelin inhibits<br>
poptosis of cardiomyocytes and endothelial cells in vitro, that repeated<br>
administration of ghrelin improves cardiac structure and function and attenuates the<br>
development of cardiac cachexia in rats with heart failure, and that ghrelin decreases<br>
systemic vascular resistance and increases cardiac output in human patients with<br>
art failure. (Id.) Thus it has been recognized that ghrelin and ghrelin agonists<br>
present potential therapeutics for the treatment of severe chronic heart failure.<br>
In a particularly preferred embodiment of each of the methods of using a<br>
relin agonist described herein the ghrelin agonist is a compound according to the<br>
rmula:<br>
H-lnp-D-Bal-D-Trp-Phe-Apc-NH2;<br>
a pharmaceutically acceptable salt thereof.<br>
A compound or compounds of the invention can be administered to a subject,<br>
"subject" refers to a mammalian or non-mammalian animal including, for example<br>
d without limitation, a human, a rat a mouse, or a farm animal. Reference to<br>
bject does not necessarily indicate the presence of a disease or disorder. Thus the<br>
25<br><br>
term subject further includes, for example, a mammalian or non-mammalian animal<br>
being closed with a ghrelin analog as part of an experiment, a mammalian or non-<br>
mammalian animal being treated to help alleviate a disease or disorder, and a<br>
mammalian or non-mammalian animal being treated prophylactically to retard or<br>
prevent the onset of a disease or disorder.<br>
Other features and advantages of the present invention are apparentfrom the<br>
additional descriptions provided herein including the different examples. The<br>
provided examples illustrate different components and methodology useful in<br>
practicing the present invention. The examples do not limit the claimed invention.<br>
Based on the present disclosure the skilled artisan can identify and employ other<br>
components and methodology useful for practicing the present invention.<br>
Unless otherwise stated, those amino acids with a chiral center are provided<br>
in the L-enantiomer. Reference to "a derivative thereof refers to a modified amino<br>
acid such as the corresponding D-amino add, a N-alkyl-amino acid, a β-amino acid,<br>
or a labeled amino add.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
The present invention features peptidyl analogs active at the GHS receptor.<br>
Human ghrelin is a 28 amino acid modified peptide where a serine hydroxyl group is<br>
esterified by n-octanoic acid. (Kojima et al. Nature 1999, 402, 656-660, and Kojima,<br>
(Abstract), Third International Symposium on Growth Hormone Secretagogues,<br>
Keystone, Colorado, USA 2000, February 17-19.)<br>
Certain amino acids present in compounds of the invention are represented<br>
herein as follows:<br>
A3c                  1-amino-1-cyclopropanecarboxylic acid<br>
A4c                  1-amino-1-cyclobutanecarboxylic acid<br>
A5c                  1-amino-1-cyclopentanecarboxylic add<br>
A6c                  1-amino-1-cyclohexanecarboxylic acid<br>
Abu                 α-aminobutyric acid<br>
Ace                  1-amino-1-cyclo(C3-C9)alkyl carboxylic acid<br><br>
Act                   4-amino-4-carboxytetrahydropyran, i.e.,:<br>
Aib                   α-aminoisobutyric acid<br>
Ala or A          alanine<br>
β-Ala               beta-alanine<br>
26<br><br><br>
Ape                 amino piperidinylcarboxylic acid, i.e.:<br>
Arg or R          arginine<br>
hArg                homoarginine<br>
Asn or N         asparagine<br>
Asp or D         aspartic acid<br><br>
Bal                  3-Benzothienylalanine, i.e.:<br><br>
Bip                  4,4'-Biphenylalanine, i.e.:<br><br>
Bpa    4-Benzoylphenylalanine, i.e.:<br>
Cha                 ß-cyclohexylalanine;<br>
Cys or C        cysteine;<br>
Dab                2,4-diaminobutyric acid, (α, γ-Diaminobutyric acid);<br>
Dap                2,3-diaminopropionic acid, (α, β-Diaminopropionicacid);<br><br>
Dip                  ß,ß-Diphenylalanine, i.e.:<br>
27<br><br>
Dhp                3,4-dehydroproline<br>
Dmt                5,5-dimethylthiazoIidine-4-carboxylic acid<br><br>
2Fua               ß-(2-furyl)-alanine, i.e.:<br>
Gln or Q         glutamine<br>
Glu or E         glutamic acid<br>
Gly or G        glycine<br>
His or H         histidine<br>
3Hyp              trans-3-hydroxy-L-proline, i.e., (2S, 3S)-3-hydroxypyrrolidine-2-<br>
carboxylic acid;<br>
4Hyp              4-hydroxyproline,      i.e.,     (2S,     4R)-4-hydroxypyrrolidine-2-<br>
carboxylic acid;<br>
lle or i             isoleucine<br>
Inc                  indoline-2-carboxylic acid<br><br>
Inp                  isonipecotic acid, i.e.:<br>
Ktp                 4-ketoproline<br>
Leu or L          leucine<br>
hLeu               homoleucine<br>
Lys or K          lysine<br>
Met or M         methionine<br>
1Nal               ß-(1-Naphthyl)alanine:<br>
2Nai               ß-(2-Naphthyf)alanine;<br>
Nle                 norieucine<br>
Nva                norvaline<br>
Oic                 octahydroindole-2-carboxylic acid<br>
Om                 omithine<br><br>
2Pal                ß-(2-Pyridyl)-alanine, i.e.,<br>
28<br><br>
3Pal                ß-(3-Pyridyt)-alanine, i.e.:<br><br>
4Pal                ß-(4-Pyridyl)-alanine, i.e.:<br><br>
Pff                  pentafluorophenylalanine, i.e.<br>
Phe or F        phenylalanine<br>
hPhe              homophenylalanine<br><br>
Pirn        '       2'-(4-PhenyI)imidazolyl, i.e.:<br>
Pip                 pipecolic acid<br>
Pro or P          proline<br>
Ser or S          serine<br><br>
Taz                 ß-(4-thiazolyl)alanine, i.e.,<br><br>
2Thi                ß-(2-thienyl)alanine, i.e.:<br><br><br><br>
3Thi                ß-(3-thienyl)alanine, i.e.:<br>
Thr or T           threonine<br>
Thz                 thiazolidine-4-carboxylic acid<br>
Tic                  1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid<br>
Tie                  tert-leucine<br>
Trp or W          tryptophan<br>
Tyr or Y            tyrosine<br>
Val or V            valine<br>
Certain other abbreviations used herein are defined as follows:<br>
Boc:                tert-butyloxycarbonyl<br>
Bzl:                 benzyl<br>
DCM:               dichloromethane<br>
DIC:                N, N-diisopropylcarbodiimide<br>
DIEA:              diisopropylethyl amine<br>
Dmab:             4-{N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-<br>
methylbutyl)-amino} benzyl<br>
DMAP:             4-(dimethylamino)pyridine<br>
DMF                dimethylformamide<br>
DNP:               2,4-dinitrophenyl<br>
Fmoc:              Fiuorenylmethyloxycarbonyl<br>
HBTU:             2-(1 H-benzotriazole-1 -yl)-1,1,3,3-tetramethyluronium<br>
hexafluorophosphate<br>
cHex               cyclohexyl<br>
HOAT:             O-(7-azabenzo1riazol-1 -yl)-1,1,3,3-tetramethyluronium<br>
hexafluorophosphate<br>
HOBt               1-hydroxy-benzotriazole<br>
HOSu:             N-hydroxysuccinimide<br>
Mmt                4-methoxytrityl<br>
NMP:               N-methylpyrrolidone<br>
Pbf:                 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl<br>
tBu:                 tert-butyl<br>
TIS:                 triisopropylsilane<br>
TOS:               tosyl<br>
30<br><br>
trt                   trityl<br>
TFA:               trifluoro acetic acid<br>
TFFH:            tetramethylfluoroforamidinium hexafluorophosphate<br>
Z:                    benzyloxycarbonyl<br>
Unless otherwise apparent, abbreviations (e.g. Ala) of amino acids in this<br>
disclosure stand for the structure of -NH-C(R)(R')-CO-, wherein R and R' each is,<br>
independently, hydrogen or the side chain of an amino acid (e.g., R = CH3 and R1 = H<br>
for Ala), or R and R1 may be joined to form a ring system.<br>
"Alkyl" refers to a hydrocarbon group containing one or more carbon atoms,<br>
where multiple carbon atoms if present are joined by single bonds. The alkyl<br>
hydrocarbon group may be straight-chain or contain one or more branches or cyclic<br>
groups.<br>
"Substituted alkyl" refers to an alkyl wherein one or more hydrogen atoms of<br>
the hydrocarbon group are replaced with one or more substituents selected from the<br>
group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN,<br>
-SH, -NH2, -NHCH3, -NO2, -C1-2 alkyl substituted with 1 to 6 halogens, -CF3, -OCH3,<br>
-OCF3, and -(CH2)0-4-COOH. In different embodiments 1, 2, 3 or 4 substituents are<br>
present The presence of -(CH2)0-4-COOH results in the production of an alkyl acid.<br>
Examples of alkyl acids containing, or consisting of, -(CH2)0-4-COOH include<br>
2-norbomane acetic acid, tert-butyric acid and 3-cyclopentyl propionic acid.<br>
"HeteroalkyI" refers to an alkyl wherein one of more of the carbon atoms in<br>
the hydrocarbon group are replaced with one or more of the following groups: amino,<br>
amido, -O-, or carbonyl. In different embodiments 1 or 2 heteroatoms are present.<br>
"Substituted heteroalkyl" refers to a heteroalkyl wherein one or more<br>
hydrogen atoms of the hydrocarbon group are replaced with one or more<br>
substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine,<br>
bromine, and iodine),-OH, -CN, -SH, -NH2, -NHCH3, -NO2, -C1-2 alkyl substituted with<br>
1 to 6 halogens, -CF3, -OCH3, -OCF3, and -(CH2)0-4-COOH. In different embodiments<br>
1, 2, 3 or 4 substituents are present.<br>
"Alkenyl" refers to a hydrocarbon group made up of two or more carbons<br>
where one or more carbon-carbon double bonds are present. The alkenyl<br>
hydrocarbon group may be straight-chain or contain one or more branches or cyclic<br>
groups.<br>
"Substituted alkenyl" refers to an alkenyl wherein one or more hydrogens are<br>
replaced with one or more substituents selected from the group consisting of halogen<br>
i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NHCH3, -NO2,<br>
C1-2 alkyl substituted with 1 to 6 halogens, -CF3, -OCH3, -OCF3, and -(CH2)0-4-COOH.<br>
31<br><br>
In different embodiments 1, 2, 3 or 4 substituents are present<br>
"Aryl" refers to an optionally substituted aromatic group with at least one ring<br>
having a conjugated pi-electron system, containing up to two conjugated or fused<br>
ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups.<br>
Preferably, the aryl is a 5 or 6 membered ring. Preferred atoms for a heterocyclic aryl<br>
are one or more sulfur, oxygen, and/or nitrogen. Examples of aryl include phenyl,<br>
1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, and 9-anthracene. Aryl<br>
substituents are selected from the group consisting of -C1-4 alkyl. -C1-4 alkoxy,<br>
halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NO2,<br>
-C1-2 alkyl substituted with 1 to 5 halogens, -CF3, -OCF3, and -(CH2)0-4-COOH. In<br>
different embodiments the aryl contains 0, 1, 2, 3, or 4 substituents.<br>
"Alkylaryl" refers to an "alkyl" joined to an "aryl".<br>
When a non-amino acid imidazole moiety, (e.g., Pirn, defined above), is<br>
present at the C-terminus of a compound of the invention it is understood that the<br>
imidazole moiety is attached to the adjacent amino acid via a pseudo-peptide bond,<br>
wherein a bond is formed between the position 2 carbon of the imidazole ring and the<br>
alpha carbon of the amino acid. For example, in the case where the adjacent amino<br>
acid is D-tryptophan (D-Trp) and the imidazole moiety is Pirn, the C-terminus of the<br>
peptide would appear as follows:<br><br>
For clarity, in the written formula for such a compound the presence of this bond is<br>
indicated by the Greek letter "Ψ" alone in parentheses. For example, the written<br>
formula H-lnp-D-Trp-D-2Nal(Ψ)-Pim denotes the structure:<br>
32<br><br><br>
The present invention includes diastereomers as well as their racemic and<br>
resolved enantiomerically pure forms. Ghrelin analogs can contain D-amino acids, L-<br>
amino acids or a combination thereof. Preferably, amino acids present in a ghrelin<br>
analog are the L-enantiomers.<br>
Preferred derivatives of analogs of the invention comprise D-amino acids, N-<br>
alkyl-amino acids, ß-amino acids, and/or one or more labeled amino acids (including<br>
a labeled version of a D-amino acid, a N-alkyl-amino acids, or a ß-amino acid). A<br>
labeled derivative indicates the alteration of an amino add or amino acid derivative<br>
with a detectable label. Examples of detectable labels include luminescent,<br>
enzymatic, and radioactive labels. Both the type of label and the position of the label<br>
can effect analog activity. Labels should be selected and positioned so as not to<br>
substantially alter the activity of the ghrelin analog at the GHS receptor. The effect of<br>
a particular label and position on ghrelin activity can be determined using assays<br>
measuring ghrelin activity and/or binding.<br>
A protecting group covalentiy joined to the C-terminal carboxy group reduces<br>
the reactivity of the carboxy terminus under in vivo conditions. The carboxy terminus<br>
protecting group is preferably attached to the α-carbonyl group of the last amino acid.<br>
Preferred carboxy terminus protecting groups include amide, methylamide, and<br>
ethylamide.<br>
Examples<br>
Examples are provided below to further illustrate different features of the<br>
present invention. The examples also illustrate useful methodology for practicing the<br>
invention. These examples do not limit the claimed invention.<br>
Synthesis<br>
The compounds of the invention can be produced using the techniques<br>
disclosed in the examples herein as well as techniques that are well known in the art.<br>
=or example, a polypeptide region  of a GHRP analog can be chemically or<br>
33<br><br>
biochemically synthesized and modified. Examples of techniques for biochemical<br>
synthesis involving the introduction of a nucleic acid into a cell and expression of<br>
nucleic acids are provided in Ausubel, Current Protocols in Molecular Biology, John<br>
Wiley, 1987-1998, and Sambrook et a/., in Molecular Cloning, A Laboratory Manual,<br>
2nd Edition, Cold Spring Harbor Laboratory Press, 1989. Techniques for chemical<br>
synthesis of polypeptides are also well known in the art (See e.g., Vincent in Peptide<br>
and Protein Drug Delivery, New York, N.Y., Dekker, 1990.) For example, the<br>
peptides of this invention can be prepared by standard solid phase peptide synthesis.<br>
(See, e.g., Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed.<br>
1984).)<br>
The substituent R1 of the above formula (1) may be attached to the free amine<br>
of the N-terminal amino acid by standard methods known in the art. For example,<br>
alkyi groups, e.g., (C1-C30)alkyl, may be attached using reductive alkyiation.<br>
Hydroxyalkyl groups, e.g., (C1-C30)hydroxyalkyl, may also be attached using<br>
reductive alkyiation wherein the free hydroxy group is protected with a t-butyl ester.<br>
Acyl groups, e.g., COE1, may be attached by coupling the free acid, e.g., E1COOH,<br>
to the free amine of the N-terminal amino acid by mixing the completed resin with 3<br>
molar equivalents of both the free acid and diisopropyicarbodiimide in methyiene<br>
chloride for about one hour. If the free acid contains a free hydroxy group, e.g., p-<br>
hydroxyphenylpropionic add, then the coupling should be performed with an<br>
additional 3 molar equivalents of HOBT.<br>
Peptides of the invention also can be and were synthesized in a parallel<br>
fashion on an ACT 396 Multiple Biomolecular Synthesizer (Advanced ChemTech,<br>
Louisville, KY), ("synthesizer"), as follows. The synthesizer was programmed to<br>
perform the following reaction cycle: (1) washing with dimethylformamide (DMF), (2)<br>
removing Fmoc protecting group with 20% piperidine in DMF for 1 X 5 min and 1 X<br>
25 min, (3) washing with DMF, (4) coupling with Fmoc amino acid for 1h at room<br>
temperature in the presence of diispropylcarbodiimide (DIC) and 1-<br>
hydroxybenzotriazole (HOBt), and (5) repeating step 4.<br>
Examples 1-65<br>
Each of the reaction wells contained 0.0675 mmol of Rink Amide MBHA resin<br>
(substitution = 0.72 mmol/g, Novabiochem, San Diego, CA). The following Fmoc<br>
amino acids (Novabiochem, San Diego, CA; Chem-lmpex International, Wood Dale,<br>
IL; SyntheTech, Albany, OR; Pharma Core, High Point, NC) were used: Fmoc-<br>
Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-H-lnp-OH, Fmoc-D-1Nal-OH, Fmoc-D-2Nal-OH,<br>
Fmoc-D-Trp(Boc)-OH, Fmoc-3Pal-OH, Fmoc-4Pal-OH, Fmoc-Orn(Boc)-OH, Fmoc-<br>
34<br><br>
D-Bip-OH, Fmoc-Thr(Bzl)-OH, Fmoc-Pff-OH, Fmoc-2Thi-OH, Fmoc-Taz-OH, Fmoc-<br>
D-Dip-OH, Fmoc-D-Bpa-OH, Fmoc-D-Bal-OH, and Fmoc-Apc(Boc)-OH.<br>
Each of the Fmoc amino acids was dissolved in a 0.3 N solution of HOBt in<br>
DMF wherein the concentration of the resulting Fmoc amino acid was 0.3 N. A four<br>
old excess (0.27 mmol, 0.9 mL of the 0.3 N solution) of Fmoc amino acid was used<br>
or each coupling. DIC (0.27 mmol, 0.6 mL of 0.45N DIC solution in DMF) was used<br>
as the coupling reagentfor each coupling. Deprotection was performed by using 20%<br>
XXXiperidinein DMF (2X1.5 mL per residue).<br>
The peptides were cleaved from the resin by treating the peptide-resins with<br>
% triisopropylsilane (TIP) in trifluoroacetic acid (TFA) (1.5 mL per reaction well) at<br>
room temperature for 2h. The resin was removed by filtration. Each filtrate was<br>
iluted to 25 mL with ether in a centrifuge tube. The resulting precipitate in each tube<br>
as centrifuged and the solvents were decanted from the precipitate. The precipitate<br>
 each tube was then dissolved in methanol (3 mL) and diluted with water (1 mL).<br>
The purification of the crude products was done on a reverse-phase preparative<br>
PLC using a column (100 X 21.20 mm, 5u) of LUNA 5u C8(2) (Phenomenex,<br>
orrance, CA). For each peptide, the column was eluted with a linear gradient from<br>
5% A and 15% B to 25% A and 75% B in 15 min with a flow rate of 25 mL/min. A<br>
as 0.1% TFA in water and B was 0.1% TFA in acetonitrile/water (80/20, v/v). The<br>
actions were checked by analytical HPLC and those containing the pure product<br>
ere combined and lyophilized to dryness.<br>
Yields ranged from 13% to 71% and purity of each of Examples 1-65<br>
ceeded 94% based upon analytical HPLC analysis. Electro-spray ionization mass<br>
ectrometry (ES-MS) analysis was performed and observed molecular weights were<br>
 agreement with calculated molecular weights. The results are detailed in Table 1,<br>
elow.<br>
xamples 66 - 69<br>
Examples 66-69 were synthesized according to the following procedure,<br>
a. BOC-(D)-Trp-OH (4.0g, 13.1mmole) (Novabiochem San Diego, Calif.) in<br>
lethanol (36ml) and Cs2CO3 (2.14g, 6.57mmole) in water (10 ml) were combined<br>
anid the mixture was swirled until a homogeneous mixture was obtained. Solvents<br>
ere removed in vacuo and the residue was dissolved in DMF (45 ml). 2-<br>
omoacetophenone(2.61g, 13.1mmole) in DMF (9 ml) was added to the solution<br>
d the solution was stirred for 30 min. at room temperature. Cesium bromide was<br>
moved by filtration and the filtrate was concentrated in vacuo. The resulting<br>
ncentrate was dissolved in xylenes (45ml), NH40Ac (17.1 g) was added, and the<br>
lution was heated at reflux for 1 hr. The cooled solution was washed two times with<br>
35<br><br>
saturated NaHCO3 solution (45 ml) and then with saturated NaCI. The resulting<br>
organic layer was purified by flash chromatography to yield 4.1 g (77%) of<br>
intermediate 1A depicted in Scheme 1 A, ("Compound 1A").<br><br>
1b. Compound 1A (403mg) was deblocked using a mixture of trifluomacetic acid<br>
(TFA) (8ml) dichloromethane (DCM) (8ml) and triisopropylsilane (TIPS) (1.4ml). After<br>
mixing for one hour the solution was concentrated under a stream of nitrogen. The<br>
residue was dissolved in DCM (40ml), washed two times with a saturated solution of<br>
NaHCO3 (40ml), and then dried over Na2C4 to yield a solution of the intermediate<br>
product 1B, depicted in Scheme 1B, below.<br><br>
1c-f. The forgoing solution of the intermediate product 1B was divided into four<br>
equal portions and coupled with the pre-activated HOBT esters of FMOC protected<br>
amino acids, as summarized in reaction schemes 1C, 1D, 1E, and 1F, below. The<br>
amino acid used for each of example 66, 67, 68 and 69 was as follows:<br>
- Ex. 66: FMOC-D-2Nal-0H (130mg, 0.30mmole) (Synthetech Albany, Oregon)<br>
- Ex. 67: FMOC-D-1Nal-0H (130mg, 0.30mmole) (Advanced Chemtech Louisville,<br>
KY)<br>
- Ex. 68: FMOC-D-Bal-0H(132mg, 0.30mmole) (Chem Impex Wood Dale, IL)<br>
- Ex. 69: FMOC-DSer(Bzl)-OH (124mg. 0.30mmole) (Chem Impex Wood Dale, IL)<br>
Each of the immediately foregoing amino acids was pre-activated with HOBT (46mg,<br>
0.30mmole) and DIC (38mg, O.30mmole) in DCM (5ml) for ten minutes   before<br>
addition to one of the four portions of the forgoing solution of the intermediate product<br>
36<br><br>
1B. The coupling reaction was then allowed to proceed for 30 minutes at room<br>
temperature.<br><br>
37<br><br><br>
1.g-j. The FMOC group is removed from each of the resulting compounds 1C, 1D,<br>
1E and 1F by addition of tris(2-aminoethyl)amine (0.9ml) to the respective reaction<br>
mixtures from the previous step and mixing for 30 minutes at room temperature. The<br>
reaction mixtures containing the deblocked compounds were then washed three<br>
times with 10% pH 5.5 phosphate buffer (10ml).<br>
The resulting free amine solutions were coupled with pre-activated HOBT<br>
esters of FMOC or BOC protected aminoacids, as follows:<br>
- Ex. 66: FMOC-lnp-OH (105mg, 0.30mmole) (Chem Impex Wood Dale, IL)<br>
- Ex. 67: FMOC-lnp-OH (105mg, 0.30mmole)<br>
- Ex. 68: BOC-lnp-OH (68.3mg, 0.30mmole) (Bachem Torrance, Calif.<br>
- Ex. 69: BOC-Aib-OH (60.6mg, 0.30mmole) (Bachem Torrance, Calif.)<br>
Each of the immediately foregoing amino acids was pre-activated with HOBT (46mg,<br>
0.30mmole) and DIC (38mg, 0.30mmo!e) in DCM (5ml) for ten minutes before<br>
addition to the appropriate deprotected amine. The coupling reaction was then<br>
allowed to proceed for one hour at room temperature.<br>
Deprotection - Compounds 66-67. The FMOC group was removed from the<br>
resulting FMOC-protected compounds by addition of tris(2-aminoethyl)amine (0.9ml)<br>
and mixing for 30 minutes. The deblocked compounds were washed three times with<br>
10% pH 5.5 phosphate buffer (10ml) and the crude products were collected as a<br>
precipitate.<br>
Deprotection - Compounds 68-69. The BOC-protected compounds were<br>
purified by flash chromatography and then deblocked for one hour with TIPS<br>
(0.50ml), TFA (0.50ml), in DCM (2.75ml). The crude products were then<br>
concentrated and dried under vacuum.<br>
Purification by HPLC afforded the products in 5% and 29% yields for the<br>
compounds of examples 66 and 67, respectively, and 15% and 43% for the<br>
compounds of examples 68 and 69, respectively.<br>
38<br><br>
The foregoing deprotection, coupling, and deprotection steps are summarized<br>
in reaction schemes 1G, 1H, 11 and 1J, below<br><br>
39<br><br><br>
Example 70:   H-lnp-D-Trp-D-2Nal(Ψ)-Pim<br>
Compound 70 was synthesized according to the following procedure.<br>
2.a.1 and 2.a.2.: Compound 2A was made in an analogous manner as was<br>
Compound 1A, using BOC-D-2Nal-OH and 2-bromoacetophenone as starting<br>
materials.<br>
Steps 2.a.1. and 2.a.2. are summarized in Scheme 2A, below.<br><br>
2.b. 1. Compound 2A (100mg, 0.242 mmole) was deblocked in TFA (2ml) and<br>
DCM (2ml) for one hour. Volatiles were then removed under a stream of nitrogen and<br>
the residue was dissolved in DCM (10ml). The resulting solution washed three times<br>
with saturated NaHCO3 (10ml) to yield a solution of Compound 2A in free amine<br>
form.<br>
2.b.2. The active ester of FMOC-D-Trp-(BOC)-OH (153mg, 0.290mmole)<br>
was preformed with N-hydroxysuccinimide (HOSu; 33mg, 0.290mmole) and DIC<br>
(37mg, 0.290mmole) in DCM (1.5ml). After one hour diisopropylurea was removed by'<br>
filtration and the filtrate was added to the Compound 2A (free amine) solution. The<br>
resulting solution was diluted with DCM to 4ml and the coupling reaction allowed to<br>
proceed for 30 minutes.<br>
40<br><br>
Steps 2.b.1. and 2.b.2. are summarized in Scheme 2B, below.<br><br>
2.C.1 Compound 2B was deblocked by addition of tris(2-aminoethyl)amine<br>
TAEA) (0.9ml) to the immediatelyforegoing coupling reaction solution and mixing for<br>
30 minutes at room temperature. The reaction solution was then washed three times<br>
with saturated NaCI solution (10ml) followed by three times with 10% pH 5.5<br>
phosphate buffer (10ml) to yield a solution of Compound 2B in free amine form..<br>
2.C.2. The active ester of BOC-lnp-OH (66.5mg, 0.290mmole) was<br>
preformed with HOSu (33mg, 0.290mmole) and DIC (37mg 0.290mmole) in DCM<br>
1.5ml). After one hour diisopropylurea was removed by filtration and the filtrate was<br>
added to the Compound 2B (free amine) solution. The resulting solution was diluted<br>
with DCM to 4ml and the coupling reaction was allowed to proceed for 12 hours.<br>
The reaction mixture was then washed three times with 10% pH 5.5<br>
phosphate buffer (10ml) and dried over Na2SO4. Solventwas removed under vacuum<br>
and the concentrate was purified by flash chromatography.<br>
2.C.3. The intermediate was deblocked using TFA (2.75ml) and TIPS (0.5ml)<br>
n DCM (2.75ml) for 30 minutes. Volatiles were removed from the reaction mixture<br>
under a stream of nitrogen and the residue was triturated with ether (15ml). After<br>
centrifugation the ether was decanted and the resulting solid was subjected to HPLC<br>
o yield purified Compound 70 in 39% yield.<br>
Steps 2.C.1. and 2.C.2. and 2.C.3. are summarized in Scheme 2C, below.<br><br>
Other peptides of the invention can be prepared by a person of ordinary skill<br>
n the art using synthetic procedures analogous to those disclosed  generally<br>
41<br><br>
hereinabove and/or to those disclosed specifically in the foregoing examples, as<br>
were the compounds depicted in Table 1.<br>
TABLE 1<br>
	Purity	Mol.Wt.	Mol.Wt.	<br>
Ex. No.                    Sequence	(Calc.)	(MS-ES)	(%)<br>
1	H-lnp-D-1NaI-D-Trp-3Pal-Lys-NH2	787.96	787.4	96<br>
2	H-lnp-D-2Nal-D-Trp-4Pal-Lys-NH2	787.96	787.4	99<br>
3	H-lnp-D-2Nal-D-Trp-Orn-Lys-NH2	753.94	753.4	98<br>
4	H-lnp-D-Bip-D-Trp-Phe-Lys-NH2	813.01	812.4	99<br>
5	H-lnp-D-2Nal-D-Trp-Thr(BzI)-Lys-NH2	831.03	830.4	98<br>
6	H-lnp-D-2Nal-D-Trp-Pff-Lys-NH2	876.92	876.3	98<br>
7	H-lnp-D-2Nal-D-Trp-Thi-Lys-NH2	793.00	792.4	98<br>
8	H-lnp-D-2Nal-D-Trp-Taz-Lys-NH2	793.99	793.4	97<br>
9	H-lnp-D-Dip-D-Trp-Phe-Lys-NH2	813.01	812.4	98<br>
10	H-lnp-D-Bpa-D-Trp-Phe-Lys-NH2	841.02	840.4	95<br>
11	H-lnp-D-2Nal-D-Bpa-Phe-Lys-NH2	852.04	851.3	99<br>
12	H-lnp-D-2Nal-D-Trp-3Pal-NH2	659.79	659.3	99<br>
13	H-lnp-D-2Nal-D-Trp-4Pal-NH2	659.79	659.3	98<br>
14	H-lnp-D-1 NaI-D-Trp-3Pal-NH2	659.79	659.3	98<br>
15	H-inp-D-Bip-D-Trp-Phe-NH2	684.84	684.3	99<br>
16	H-lnp-D-2Nal-D-Trp-Thr(Bzl)-NH2	702.85	702.3	99<br>
17	H-lnp-D-2Nal-D-Trp-Pff-NH2	748.75	748.2	99<br>
18	H-lnp-D-2Nal-D-Trp-2Thi-NH2	664.83	6642	99<br>
19	H-lnp-D-2Nal-D-Trp-Taz-NH2	665.82	665.3	98<br>
20	H-lnp-D-Dip-D-Trp-Phe-NH2	684.84	684.3	98<br>
21	H-lnp-D-2Nal-D-Dip-Phe-NH2	695.86	695.3	99<br>
22	H-lnp-D-Bal-D-Trp-Phe-NH2	664.83	664.3	97<br>
23	H-lnp-D-2Nal-D-Bal-Phe-NH2	675.85	6752	99<br>
24	H-lnp-D-2Nal-D-Trp-3Pal-Lys-NH2	787.96	787.5	97<br>
25	H-lnp-D-Bal-D-Trp-2Thi-Lys-NH2	799.03	798.4	99<br>
26	H-lnp-D-Bal-D-Trp-Phe-Lys-NH2	793.00	792.4	99<br>
27	H-lnp-D-1 Nal-D-Trp-2Thi-Lys-NH2	793.00	792.4	99<br>
28	H-lnp-D-2Nal-D-Trp-Phe-Apc-NH2	784.96	784.4	98<br>
29	H-lnp-D-1 Nal-D-Trp-Phe-Apc-NH2	784.96	784.4	98<br>
30	H-lnp-D-Bal-D-Trp-Phe-Apc-NH2	790.99	790.4	97<br>
31	H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2	801.99	801.4	98<br>
32	H-Apc-D-1Nal-D-Trp-2Thi-Lys-NH2	808.02	807.4	99<br>
42<br><br>
33	H-lnp-D-1Nal-D-Trp-2Thi-NH2	664.83	6642	98<br>
34	H-Apc-D-1Nal-D-Trp-Phe-NH2	673.81	673.3	99<br>
35	H-lnp-D-1Nal-D-Trp-Taz-Lys-NH2	793.99	793.5	99<br>
36	H-lnp-D-Bal-D-Trp-Taz-Lys-NH2	800.02	799.4	99<br>
37	H-Apc-D-1Nal-D-Trp-Taz-Lys-NH2	809.00	808.5	99<br>
38	H-Apc-D-Bal-D-Trp-Taz-Lys-NH2	815.03	814.4	99<br>
39	H-Apc-D-Bal-D-Trp-2Thi-Lys-NH2	814.04	813.4	98<br>
40	H-lnp-D-1Nal-D-Trp-2Thi-Apc-NH2	790.99	790.5	97<br>
41	H-lnp-D-Bal-D-Trp-2Thi-Apc-NH2	797.01	796.4	97<br>
42	H-Apc-D-1Nal-D-Trp-2Thi-Apc-NH2	806.00	805.5	97<br>
43	H-Apc-D-Bal-D-Trp-2Thi-Apc-NH2	812.03	811.4	98<br>
44	H-Apc-D-1Nal-D-Trp-Phe-Lys-NH2	801.99	801.5	98<br>
45	H-Apc-D-Bal-D-Trp-Phe-Lys-NH2	808.02	807.5	99<br>
46	H-Apc-D-1Nal-D-Trp-Phe-Apc-NH2	799.97	799.5	98<br>
47	H-Apc-D-Bal-D-Trp-Phe-Apc-NH2	806.00	805.5	98<br>
48	H-Apc-D-1Nal-D-1Nal-Phe-Apc-NH2	811.00	810.5	95<br>
49	H-Apc-D-1Nal-D-2Nal-Phe-Apc-NH2	811.00	8105	96<br>
50	H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH2	813.01	812.5	99<br>
51	H-Apc-D-Bal-D-1Nal-Phe-Apc-NH2	817.02	816.5	96<br>
52	H-Apc-D-Bal-D-2Nal-Phe-Apc-NH2	817.02	816.5	94<br>
53	H-Apc-D-Bal-D-1Nal-Phe-Lys-NH2	819.04	818.5	99<br>
54	H-Apc-D-Bal-D-2Nal-Phe-Lys-NH2	819.04	818.5	98<br>
55	H-Apc-D-1Nal-D-Trp-2Thi-NH2	679.84	6792	98<br>
56	H-Apc-D-Bal-D-Trp-Phe-NH2	679.84	679.3	99<br>
57	H-Apc-D-1 Nal-D-Trp-Taz-NH2	680.83	680.3	99<br>
58	H-Apc-D-Bal-D-Trp-2Thi-NH2	68537	6852	97<br>
59	H-Apc-D-Bal-D-Trp-Taz-NH2	686.86	686.2	99<br>
60	H-Apc-D-2Nal-D-Trp-2Thi-NH2	679.84	6792	95<br>
31	H-Apc-D-2Nal-D-Trp-Taz-NH2	680.83	6802	97<br>
32	H-lnp-D-1Nal-D-Trp-Taz-Apc-NH2	791.97	791.5	98<br>
33	H-lnp-D-Bal-D-Trp-Taz-Apc-NH2	798.00	797.4	99<br>
34	H-Apc-D-1Nal-D-Trp-Taz-Apc-NH2	806.99	806.5	99<br>
35	H-Apc-D-Bal-D-Trp-Taz-Apc-NH2	813.02	812.4	98<br>
36	H-lnp-D-2Nal-D-Trp(Ψ)-Pim	610.77	611.4	99<br>
37	H-lnp-D-1Nal-D-Trp(Ψ)-Pim	610.77	611.3	99<br>
58	H-lnp-D-Bal-D-Trp(Ψ)-Pim	616.79	617.3	99<br>
19	H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim	564.69	565.3	99<br>
43<br><br>
70	H-lnp-D-Trp-D-2Nal(Ψ)-Pim	610.77	611.4	99<br>
Biological Assay<br>
The activities of compounds of the invention at the GHS receptor can be and<br>
were determined using techniques such as those described in the examples provided<br>
below. In different embodiments a ghrelin analog has at least about 50%, at least<br>
about 60%, at least about 70%, at least about 80%, or at least about 90%, functional<br>
activity relative to ghrelin as determined using one or more of the Functional Activity<br>
assays described below; and/or has an IC50 greater than about 1,000 nM, greater<br>
than about 100 nM, or greater than about 50 nM, using the Receptor Binding assay<br>
described below. With respect to ICso, greater refers to potency and thus indicates a<br>
lesser amount is needed to achieve binding inhibition.<br>
Assays measuring the ability of a compound to bind a GHS receptor employ a<br>
GHS receptor, a fragment of the receptor comprising a ghrelin binding site, a<br>
polypeptide comprising such a fragment, or a derivative of the polypeptide.<br>
Preferably, the assay uses the GHS receptor or a fragment thereof. A polypeptide<br>
comprising a GHS receptor fragment that binds ghrelin can also contain one or more<br>
polypeptide regions not found in a GHS receptor. A derivative of such a polypeptide<br>
comprises a GHS receptor fragment that binds ghrelin along with one or more non-<br>
peptide components.<br>
The GHS receptor amino acid sequence involved in binding can be readily<br>
identified using labeled ghrelin or ghrelin structural or functional analogs and different<br>
receptor fragments. Different strategies can be employed to select fragments to be<br>
tested to narrow down the binding region. Examples of such strategies include<br>
testing consecutive fragments about 15 amino acids in length starting at the N-<br>
terminus, and testing longer length fragments. If longer length fragments are tested,<br>
a fragment binding ghrelin can be subdivided to further locate the ghrelin binding<br>
region. Fragments used for binding studies can be generated using recombinant<br>
nucleic acid techniques.<br>
Binding assays can be performed using individual compounds or preparations<br>
containing different numbers of compounds. A preparation containing different<br>
numbers of compounds having the ability to bind to the GHS receptor can be divided<br>
into smaller groups of compounds that can be tested to identify the compound(s)<br>
binding to the GHS receptor, in an embodiment of the present invention, a test<br>
preparation containing at least 10 compounds is used in a binding assay.<br>
Binding assays can be performed using recombinantly produced GHS<br>
receptor polypeptides present in different environments. Such environments include,<br>
44<br><br>
for example, cell extracts and purified cell extracts containing the GHS receptor<br>
polypeptide expressed from, recombinant nucleic acid or naturally occurring nucleic<br>
acid; and also include, for example, the use of a purified GHS receptor polypeptide<br>
produced by recombinant means or from naturally occurring nucleic acid which is<br>
introduced into a different environment.<br>
Screening for GHS Receptor Active Compounds<br>
Screening for GHS receptor active compounds is facilitated using a<br>
recombinantly expressed receptor. Using a recombinantly expressed GHS receptor<br>
offers several advantages such as the ability to express the receptor in a defined cell<br>
system so that a response to a compound at the GHS receptor can more readily be<br>
differentiated from responses at other receptors. For example, the GHS receptor can<br>
be expressed in a cell line such as HEK 293, COS 7, and CHO not normally<br>
expressing the receptor by an expression vector, wherein the same ceil line without<br>
the expression vector can act as a control.<br>
Screening for compounds reducing GHS receptor activity is facilitated through<br>
the use of a ghrelin functional analog in the assay. The use of a ghrelin functional<br>
analog in a screening assay provides for GHS receptor activity. The effect of test<br>
compounds on such activity can be measured to identify, for example, allosteric<br>
modulators and antagonists.<br>
GHS receptor activity can be measured using different techniques such as<br>
detecting a change in the intracellular conformation of the GHS receptor, in the G-<br>
protein coupled activities, and/or in the intracellular messengers. Preferably, GHS<br>
receptor activity is measured using techniques such as those measuring intracellular<br>
Ca2+. Examples of techniques well known in the art that can be employed to measure<br>
Ca2+ include the use of dyes such as Fura-2 and the use of Ca2+-bioluminescent<br>
sensitive reporter proteins such as aequorin. An example of a cell line employing<br>
aequorin to measure G-protein activity is HEK293/aeq17. (Button et a/.,1993. Cell<br>
Calcium 14, 663-671, and Feighner et al., 1999, Science 284, 2184-2188.)<br>
Chimeric receptors containing a ghrelin binding region functionaly coupled to<br>
a different G-protein can also be used to measure GHS receptor activity. A chimeric<br>
GHS receptor contains an N-terminal extracellular domain; a transmembrane domain<br>
made up of transmembrane regions, extracellular loop regions, and intracellular loop<br>
regions; and an intracelluiar carboxy terminus. Techniques for producing chimeric<br>
receptors and measuring G-protein coupled responses are provided in, for example,<br>
International Application Number WO 97/05252, and U.S. Patent Number 5,264,565,<br>
both of which are hereby incorporated by reference herein.<br>
Stimulation of GHS Receptor Activity<br>
45<br><br>
Structural and/or functional analogs of ghrelin can be used to stimulate GHS<br>
receptor activity. Such stimulation can be used, for example, to study the effect of<br>
GHS receptor modulation, to study the effect of growth hormone secretion, to look for<br>
or study ghrelin antagonists, or to achieve a beneficial effect in a subject. Beneficial<br>
effects that can be achieved include one or more of the following: treating a growth<br>
hormone deficient state, increasing muscle mass, increasing bone density, treating<br>
sexual dysfunction in males or females, facilitating a weight gain, facilitating<br>
maintenance of weight, facilitating maintenance of physical functioning, facilitating<br>
recovery of physical function, and/or facilitating appetite increase.<br>
Increasing weight or appetite can be useful for maintaining weight or<br>
producing a weight or appetite gain in an underweight subject, or in a patient having<br>
a disease or undergoing treatment that affects weight or appetite. In addition, for<br>
example, farm animals such as pigs, cows and chickens can be treated to gain<br>
weight.<br>
Underweight subjects include those having a body weight about 10% or less,<br>
20% or less, or 30% or less, than the lower end of a "normal" weight range or Body<br>
Mass Index ("BMI"). BMI measures a subject's height/weight ratio and is determined<br>
by calculating weight in kilograms divided by the square of height in meters. BMI<br>
measures your height/weight ratio. It is determined by calculating weight in kilograms<br>
divided by the square of height in meters. The BMI "normal" range for humans is<br>
generally considered to be 19-22. "Normal" weight ranges are well known in the art<br>
and take into account factors such as a subject age, height, and body type.<br>
Biological Assays - Examples<br>
1. Receptor Binding Assay<br>
A. Preparation of CHO-K1 cells expressing the human recombinant GHS<br>
receptor<br>
The cDNA for human growth hormone secretagogue receptor (hGHS-R, or<br>
ghrelin receptor) was cloned by Polymerase Chain Reaction (PCR) using human<br>
brain RNA as a template (Clontech, Palo Alto, CA), gene specific primers flanking the<br>
full-length coding sequence of hGHS-R, (S:5'-ATGTGGAACGCGACGCC<br>
CAGCGAAGAG-3'(SEQ ID NO:) and AS: 5'-TCATGTATTAATAC<br>
TAGATTCTGTCCA-3') (SEQ ID NO:2), and Advantage 2 PCR Kit<br>
(Clontech). The PCR product was cloned into the pCR2.1 vector using Original TA<br>
Cloning Kit (Invitrogen, Carlsbad, CA). The full length human GHS-R was subcloned<br>
into the mammalian expression vector pcDNA 3.1 (Invitrogen). The plasmid was<br>
ransfected into the Chinese hamster ovary cell line, CHO-K1 (American Type<br>
Culture Collection, Rockville, MD), by calcium phosphate method (Wigler, M et al.,<br>
46<br><br>
Cell 11, 223, 1977). Single cell clones stably expressing the hGHS-R were obtained<br>
by selecting transfected cells grown in cloning rings in RPMI 1640 media<br>
supplemented with 10 % fetal bovine serum and 1 mM sodium pyruvate containing<br>
0.8 mg/ml G418 (Gibco, Grand Island, NY).<br>
B. GHS-R Binding Assay:<br>
Membranes for radioligand binding studies can be and were prepared by<br>
homogenization of the foregoing CHO-K1 cells expressing the human recombinant<br>
GHS receptor in 20 ml of ice-cold 50 mM Tris-HCI with a Brinkman Polytron<br>
(Westbury, NY) (setting 6, 15 sec). The homogenates were washed twice by<br>
centrifugation (39,000 g/10 min), and the final pellets were resuspended in 50 mM<br>
Tris-HCI, containing 2.5 mM MgCI2, and 0.1% BSA. For assay, aliquots (0.4 ml) were<br>
incubated with 0.05 nM (125l)ghrelin (~2000 Cl/mmol, Perkin Elmer Life Sciences,<br>
Boston, MA), with and without 0.05 ml of unlabeled competing test compounds of the<br>
invention. After a 60 min incubation (4°C), the bound (125l)ghrelin was separated<br>
from the free by rapid filtration through GF/C filters (Brandel, Gaithersburg, MD),<br>
which had been previously soaked in 0.5% polyethyleneimine/0.1% BSA. The filters<br>
were then washed three times with 5-ml aliquots of ice-cold 50 mM Tris-HCI and<br>
0.1% bovine serum albumin, and the bound radioactivity trapped on the filters was<br>
counted by gamma spectrometry (Wallac LKB, Gaithersburg, MD). Specific binding<br>
was defined as the total (125l)ghrelin bound minus that bound in the presence of 1000<br>
nM ghrelin (Bachem, Torrence, CA).<br>
2. GHS-R Functional Activity Assays<br>
A.  In vitro GSH Receptor Mediated Intracellular Ca2+ Mobilization<br>
The foregoing CHO-K1 cells expressing the human GSH receptor were<br>
harvested by incubating in a 0.3% EDTA/phosphate buffered saline solution (25° C),<br>
and washed twice by centrifugation. The washed cells were resuspended in Hank's -<br>
buffered saline solution (HBSS) for loading of the fluorescent Ca2* indicator Fura-<br>
2AM. Cell suspensions of approximately 108 cells/ml were incubated with 2 µM Fura-<br>
2AM for 30 min at about 25 °C. Unloaded Fura-2AM was removed by centrifugation<br>
twice in HBBS, and the final suspensions were transferred to a spectrofluorometer<br>
(Hitachi F-2000) equipped with a magnetic stirring mechanism and a temperature-<br>
regulated cuvette holder. After equilibrafon to 37°C, the compounds of the invention<br>
were added for measurement of intracellular Ca2+ mobiization. The excitation and<br>
emission wavelengths were 340 and 510 nm, respectively.<br>
B.  In vivo GH Release/Suppression<br>
As is well known in the art, compounds may be tested for their ability to<br>
47<br><br>
stimulate or suppress release of growth hormone (GH) in vivo. (See, e.g.,<br>
Deghenghi, R., et al., Life Sciences 54, 1321-1328 (1994); International Application<br>
No. WO 02/08250.) Thus for example in order to ascertain a compound's ability to<br>
stimulate GH release in vivo the compound may be injected subcutaneously in 10-<br>
day old rats at a dose of, e.g., 300 mg/kg. The circulating GH may be determined at,<br>
e.g., 15 minutes after injection and compared to GH levels in rats injected with a<br>
solvent control.<br>
Similarly, compounds may be tested for their ability to antagonize ghrelin-<br>
induced GH secretion in vivo. Thus a compound may be injected subcutaneously in<br>
10-day old rats at a dose of, e.g., 300 mg/kg, along with ghrelin. Again the circulating<br>
GH may be determined at, e.g., 15 minutes after injection and compared to GH levels<br>
in rats injected with ghrelin alone.<br>
Administration<br>
The compounds of the invention can be formulated and administered to a<br>
subject using the guidance provided herein along with techniques well known in the<br>
art. The preferred route of administration ensures that an effective amount of<br>
compound reaches the target. Guidelines for pharmaceutical administration in<br>
general are provided in, for example, Remington's Pharmaceutical Sciences 18th<br>
Edition, Ed. Gennaro, Mack Publishing, 1990, and Modem Phamtaceutics 2nd<br>
Edition, Eds. Banker and Rhodes, Marcel Dekker, Inc., 1990, both of which are<br>
hereby incorporated by reference herein.<br>
The compounds of the invention can be prepared as acidic or basic salts.<br>
Pharmaceutically acceptable salts (in the form of water- or oil-soluble or dispersible<br>
products) include conventional non-toxicsalts or the quaternary ammonium salts that<br>
are formed, e.g., from inorganic or organic acids or bases. Examples of such salts<br>
include acid addition salts such as acetate, adipate, alginate, aspartate, benzoate,<br>
benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsutfonate,<br>
cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate,<br>
glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate,<br>
hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate,<br>
maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate,<br>
pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate,<br>
tartrate, thiocyanate, tosylate, and undecanoate; and base salts such as ammonium<br>
salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal<br>
salts such as calcium and magnesium salts, salts with organic bases such as<br>
dicyclohexylamine salts, N-methyi-D-glucamine, and salts with amino acids such as<br>
arginine and lysine.<br>
48<br><br>
The compounds of the invention can be administered using different routes<br>
including oral, nasal, by injection, transdermal, and transmucosally. Active<br>
ingredients to be administered orally as a suspension can be prepared according to<br>
techniques well known in the art of pharmaceutical formulation and may contain<br>
microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a<br>
suspending agent, methylcellulose as a viscosity enhancer, and sweeteners/flavoring<br>
agents. As immediate release tablets, these compositions may contain<br>
microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and<br>
lactose and/or other excipients, binders, extenders, disintegrants, diluents and<br>
lubricants.<br>
Administered by nasal aerosol or inhalation formulations may be prepared, for<br>
example, as solutions in saline, employing benzyl alcohol or other suitable<br>
preservatives, absorption promoters to enhance bioavailabiity, employing<br>
fluorocarbons, and/or employing other soiubilizing or dispersing agents.<br>
The compounds of the invention may also be administered in intravenous<br>
(both bolus and infusion), intraperitoneal, subcutaneous, topical with or without<br>
occlusion, or intramuscular form. When administered by injection, the injectable<br>
solution or suspension may be formulated using suitable non-toxic, parenterally-<br>
acceptable diluents or solvents, such as Ringer's solution or isotonic sodium chloride<br>
solution, or suitable dispersing or wetting and suspending agents, such as sterile,<br>
bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including<br>
oleic acid.<br>
Suitable dosing regimens are preferably determined taking into account<br>
actors well known in the art including type of subject being dosed; age, weight, sex<br>
and medical condition of the subject; the route of administration; the renal and<br>
epatic function of the subject; the desired effect; and the particular compound<br>
mployed.<br>
Optimal precision in achieving concentrations of drug within the range that<br>
fields efficacy without toxicity requires a regimen based on the kinetics of the drug's<br>
valiability to target sites. This involves a consideration of the distribution,<br>
quilibrium, and elimination of a drug. The daily dose for a subject is expected to be<br>
etween 0.01 and 1,000 mg per subject per day.<br>
The compounds of the invention can be provided in a kit. Such a kit typically<br>
contains an active compound in dosage forms for administration. A dosage form<br>
contains a sufficient amount of active compound such that a desirable effect can be<br>
btained when administered to a subject during regular intervals, such as 1 to 6<br>
nes a day, during the course of 1 or more days. Preferably, a kit contains<br>
49<br><br>
nstructions indicating the use of the dosage form to achieve a desirable affect and<br>
the amount of dosage form to be laken over a specified time period.<br>
The invention has been described in an illustrative manner, and it is to be<br>
understood that the terminology which has been used is intended to be in the nature<br>
of words of description rather than of limitation. Obviously, many modifications and<br>
variations of the present invention are possible in light of the above teachings. It is,<br>
therefore, to be understood that within the scope of the appended claims the<br>
invention may be practiced otherwise than as specifically described.<br>
The patent and scientific literature referred to herein represents knowledge<br>
that is available to those with skill in the art. All patents, patent publications and other<br>
publications cited herein are hereby incorporated by reference in their entirety.<br>
Other Embodiments<br>
it is to be understood that whiie the invention has been described in<br>
conjunction with the detailed description thereof, that the foregoing description is<br>
intended to illustrate and not limit the scope of the invention, which is defined by the<br>
scope of the appended claims. Other aspects, advantages, and modifications are<br>
wthin the claims.<br>
50<br><br>
WE CLAIM :<br>
1.   A compound according to the formula:<br>
H-Inp-D-2Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-2Nal-D-Trp-4Pal-NH2;<br>
H-Inp-D-lNal-D-Trp-3Pal-NH2;<br>
H-Inp-D-Bip-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Inp-D-2Nal-D-Trp-3Thi-NH2;<br>
H-Inp-D-Dip-D-Trp-Phe-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Bal-Phe-NH2;<br>
H-Inp-D-lNal-D-Trp-2Thi-NH2; or<br>
H-Apc-D- lNal-D-Trp-Phe-NH2;<br>
or a pharmaceutically acceptable salt thereof as herein described.<br>
2.   A compound according to the formula:<br>
H-Inp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-NH2;<br>
H-Inp-D-1Nal-D-Trp-2Thi-NH2; or<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
or a pharmaceutically acceptable salt thereof as herein described.<br>
3.   A compound according to the formula:<br>
H-Apc-D- lNal-D-Trp-Phe-Lys-NH2;<br>
or a pharmaceutically acceptable salt thereof as herein described.<br>
4.   A compound according to the formula:<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D- 1Nal-D-1Nal-Phe-Lys-NH2;<br><br>
H-Inp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D- 1Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Bal-D-Trp(Ψ)-Pim;<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Trp-D^Nal(Ψ)-Pim; or<br>
H-Inp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
or a pharmaceutically acceptable salt thereof as herein described.<br>
5. A method of curing or preventing or reducing the onset of or severity of a disease<br>
or disorder by administering a ghrelin analogue selected from the list consisting of:<br>
H-Inp-D-2Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-2Nal-D-Trp-4Pal-NH2;<br>
H-Inp-D-1Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-Bip-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Inp-D-2Nal-D-Trp-3Thi-NH2;<br>
H-Inp-D-Dip-D-Trp-Phe-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Bal-Phe-NH2;<br>
H-Inp-D- lNal-D-Trp-2Thi-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH2;<br>
H-Inp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D- 1Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Bal-D-Trp(Ψ)-Pim;<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Trp-D-2Nal(Ψ)-Pim; and<br>
H-Inp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
or a pharmaceutically acceptable salt thereof as herein described, wherein said effective<br>
amount is effective for producing a beneficial effect in helping to treat (e.g., cure or reduce<br><br>
the severity) or prevent (e.g., reduce the likelihood of onset or severity) a disease or<br>
disorder.<br>
6.  A method for stimulating growth hormone secretion in a subject in need of such<br>
stimulation comprising the step of administering to a subject an effective amount of a<br>
ghrelin agonist according to formula:<br>
H-Inp-D-2Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-2Nal-D-Trp-4Pal-NH2;<br>
H-Inp-D-1Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-Bip-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Inp-D-2Nal-D-Trp-3Thi-NH2;<br>
H-Inp-D-Dip-D-Trp-Phe-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Bal-Phe-NH2;<br>
H-Inp-D-1Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH2;<br>
H-Inp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-lNal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Bal-D-Trp(Ψ)-Pim;<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Trp-D-2Nal(Ψ)-Pim; or<br>
H-Inp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
or a pharmaceutically acceptable salt thereof as herein described, wherein said effective<br>
amount is at least an amount sufficient to produce a detectable increase in growth hormone<br>
secretion and, preferably, in an amount sufficient to achieve a beneficial effect in a patient.<br>
7.   A method according to claim 6 wherein said stimulation of growth hormone<br>
secretion is indicated for treatment of a growth hormone deficiency state, for increasing<br>
muscle mass, for increasing bone density, for sexual dysfunction in males or females, for<br>
facilitating   a  weight  gain,   for  facilitating  maintenance   of weight,   for  facilitating<br>
maintenance of physical functioning, for facilitating recovery of physical function, and/or<br>
facilitating appetite increase.<br>
53<br><br>
8.   A method according to claim 7 wherein said facilitating weight gain, facilitating<br>
maintenance in weight and/or facilitating appetite increase is indicated in a patient having a<br>
disease or disorder, or undergoing a treatment, accompanied by weight loss.<br>
9.   A method according to claim 8 wherein said diseases or disorders accompanied<br>
by weight loss includes anorexia, bulimia, cancer cachexia, AIDS, AIDS wasting, cachexia,<br>
and wasting in frail elderly.<br>
10.  A method according to claim 8 wherein said treatments accompanied by weight<br>
loss include chemotherapy, radiation therapy, temporary or permanent immobilization, and<br>
dialysis.<br>
11. A method of eliciting a ghrelin agonist effect in a subject, comprising the step of<br>
administering to a subject an effective amount of a ghrelin agonist according to the<br>
formula:<br>
H-Inp-D-2Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-2Nal-D-Trp-4Pal-NH2;<br>
H-Inp-D-1Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-Bip-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Inp-D-2Nal-D-Trp-3Thi-NH2;<br>
H-Inp-D-Dip-D-Trp-Phe-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Bal-Phe-NH2;<br>
H-Inp-D-1Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH2;<br>
H-Inp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-1Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Bal-D-Trp(Ψ)-Pim;<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Trp-D-2Nal(Ψ)-Pim; or<br>
H-Inp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
54<br><br>
or a pharmaceutically acceptable salt thereof as herein described, wherein said effective<br>
amount is at least an amount sufficient to produce a detectable increase in growth hormone<br>
secretion and, preferably, in an amount sufficient to achieve a beneficial effect in a patient.<br>
12.   A method of achieving a beneficial cardiovascular effect in a subject in need<br>
thereof, comprising the step of administering to a subject an effective amount of a ghrelin<br>
agonist according to formula:<br>
H-Inp-D-2Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-2Nal-D-Trp-4Pal-NH2;<br>
H-Inp-D-1Nal-D-Trp-3Pal-NH2;<br>
H-Inp-D-Bip-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Trp-2Thi-NH2;<br>
H-Inp-D-2Nal-D-Trp-3Thi-NH2;<br>
H-Inp-D-Dip-D-Trp-Phe-NH2;<br>
H-Inp-D-Bal-D-Trp-Phe-NH2;<br>
H-Inp-D-2Nal-D-Bal-Phe-NH2;<br>
H-Inp-D-1Nal-D-Trp-2Thi-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-NH2;<br>
H-Apc-D-1Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
H-Apc-D-1Nal-D-1Nal-Phe-Lys-NH2;<br>
H-Inp-D-2Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-1Nal-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Bal-D-Trp(Ψ)-Pim;<br>
H-Aib-D-Ser(Bzl)-D-Trp(Ψ)-Pim;<br>
H-Inp-D-Trp-D-2Nal(Ψ)-Pim; or<br>
H-Inp-D-2Nal-D-Trp-Phe-Lys-NH2;<br>
or a pharmaceutically acceptable salt thereof as herein described, wherein said effective<br>
amount is at least an amount sufficient to produce a beneficial effect in said subject.<br>
13.   A method according to claim 12, wherein said beneficial cardiovascular effect<br>
comprises inhibition of apoptosis of cardiomyocytes, cardiac endothelial cells, or vascular<br>
endothelial cells.<br>
14.   A method according to claim 12, wherein said beneficial cardiovascular effect<br>
comprises improvement of cardiac structure or function.<br>
55<br><br>
15.   A method according to claim 12, wherein said beneficial cardiovascular effect<br>
comprises attenuation of the development of cardiac cachexia.<br>
16.   A method according to claim 12, wherein said beneficial cardiovascular effect<br>
comprises a reduction in systemic vascular resistance.<br>
17.   A method according to claim 12, wherein said beneficial cardiovascular effect<br>
comprises an increase in cardiac output.<br>
18.  A method according to any one of claims 12-17, wherein said subject comprises<br>
a human.<br>
Dated this 9th day of April 2007<br><br>
56<br><br>
The instant invention discloses compounds which are  ghrelin analogues  and<br>
pharmaceutically acceptable salts thereof capable of exhibiting ghrelin agonist activity.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1ncGEucGRm" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyMjkta29sbnAtMjAwNy1zZXF1ZW5jZSBsaXN0aW5nLnBkZg==" target="_blank" style="word-wrap:break-word;">01229-kolnp-2007-sequence listing.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LSgwMi0wNy0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-(02-07-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LSgwNC0wOS0yMDE0KS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-(04-09-2014)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LSgwNC0wOS0yMDE0KS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-(04-09-2014)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LSgwNC0wOS0yMDE0KS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-(04-09-2014)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUFCU1RSQUNUIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-ABSTRACT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUFNQU5ERUQgUEFHRVMgT0YgU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-AMANDED PAGES OF SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUNBTkNFTExFRCBQQUdFUy5wZGY=" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-CANCELLED PAGES.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIE9USEVSUyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-CORRESPONDENCE OTHERS 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUZPUk0gMSAxLjEucGRm" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-FORM 1 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUZPUk0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUZPUk0gMiAxLjEucGRm" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-FORM 2 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LUZPUk0gMyAxLjEucGRm" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-FORM 3 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnRpZg==" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-PETITION UNDER RULE 137.tif</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIyOS1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1229-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="263330-open-drive-scroll-machine.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="263332-a-device-for-oil-conservation-in-a-lube-oil-ventilation-system-adaptable-to-gas-turbines.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>263331</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1229/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>43/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>24-Oct-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>20-Oct-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>09-Apr-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SOCIETE DE CONSEIL DE RECHERCHES ET D&#x27;APPLICATIONS SCIENTIFIQUES, S.A.S.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>51-53, RUE DU DOCTEUR BLANCHE, F-75016, PARIS</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ZHENG XIN DONG</td>
											<td>66 FAIRVIEW STREET, HOLLISTON, MA 01746</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07K 14/60</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2003/024834</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-08-08</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/402,263</td>
									<td>2002-08-09</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/263331-a-ghrelin-analogue by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:22:13 GMT -->
</html>
